We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Metz

David C. Metz MD

Professor of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Dr. Metz is Professor of Medicine and Associate Chief for Clinical Affairs in the Division of Gastroenterology at the University of Pennsylvania in Philadelphia, where he is the director of the Acid-Peptic Disease Program and codirector of the GI Physiology Laboratory, the Swallowing Disorders Program, and the Neuroendocrine Tumor Program.

Dr. Metz earned his MBBCh (MD equivalent) from the University of the Witwatersrand in Johannesburg, South Africa. After moving to the United States in 1986, he pursued a residency in internal medicine at Albert Einstein Medical Center in Philadelphia. He completed a fellowship in gastroenterology in the combined Georgetown/Veterans Affairs Medical Center/National Institutes of Health (NIH) program Washington, DC, where he remained on staff for 2 more years as a senior staff fellow.

He is actively involved in clinical research, patient care, and teaching of students, residents, and fellows. Dr. Metz’s clinical research program is particularly active in acid-peptic conditions, including hypersecretory states such as Zollinger-Ellison syndrome, Helicobacter pylori infection, nonsteroidal anti-inflammatory drug gastropathy, and gastroesophageal reflux disease. He also has particular expertise in the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. He has been a principal investigator on a number of trials evaluating upper gastrointestinal disease states. He is also active in national gastroenterology societies and was a prior member of the Liason Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative) and the US Food and Drug Administration Gastrointestinal Drugs Advisory Committee.